Business Context and Reporting Period
This Form 8-K filing by Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reports on events occurring on September 21, 2022. The Company is a Delaware corporation and an emerging growth company focused on pharmaceutical development, with its principal executive offices in Rockville, Maryland.
Key Financial Metrics
The filing details the closing of an overallotment option related to the Company's Initial Public Offering (IPO). Key financial figures include:
- Overallotment Units Sold: 183,883 Units
- Price Per Unit: $8.125
- Gross Proceeds from Overallotment: $1,494,049
- Total IPO Gross Proceeds (Initial + Overallotment): $11,454,389 ($9,960,340 initial + $1,494,049 overallotment)
- Net Proceeds: Not specified; filing notes amounts are before deducting underwriter commissions and discounts.
The filing does not provide data on operating revenue, profit, cash flow, margins, or existing debt levels, as this report focuses solely on the capital raise event.
Material Changes
The primary material change is the increase in the Company's capitalization and cash liquidity resulting from the exercise of the overallotment option. This transaction increased the total number of Units sold in the IPO from 1,225,888 to 1,409,771. The Warrants included in the Units were exercised simultaneously with the closing of the offering.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosures inherent in an IPO closing. The document confirms the entry into a material definitive agreement (the Underwriting Agreement) with Boustead Securities, LLC, acting as the lead underwriter.
Investor Verification Checklist
- Verify the net proceeds after deducting underwriting commissions and discounts, as only gross proceeds are listed.
- Confirm the total number of outstanding shares post-IPO, including the impact of the simultaneous warrant exercises.
- Review the full Underwriting Agreement for lock-up periods and specific underwriter obligations.
- Check subsequent filings for the allocation of the raised capital and the Company's cash runway.